XRTX Stock Overview
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
XORTX Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.51 |
| 52 Week High | CA$7.52 |
| 52 Week Low | CA$1.98 |
| Beta | -0.082 |
| 1 Month Change | -25.30% |
| 3 Month Change | 9.61% |
| 1 Year Change | -59.37% |
| 3 Year Change | -85.15% |
| 5 Year Change | -82.86% |
| Change since IPO | -83.41% |
Recent News & Updates
Shareholder Returns
| XRTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.3% | 0.6% | 0.6% |
| 1Y | -59.4% | 13.1% | 25.7% |
Return vs Industry: XRTX underperformed the US Pharmaceuticals industry which returned 12.9% over the past year.
Return vs Market: XRTX underperformed the US Market which returned 25.7% over the past year.
Price Volatility
| XRTX volatility | |
|---|---|
| XRTX Average Weekly Movement | 22.9% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: XRTX's share price has been volatile over the past 3 months.
Volatility Over Time: XRTX's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 3 | Allen Davidoff | www.xortx.com |
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
XORTX Therapeutics Inc. Fundamentals Summary
| XRTX fundamental statistics | |
|---|---|
| Market cap | US$7.06m |
| Earnings (TTM) | -US$2.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.3x
P/E RatioIs XRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XRTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.16m |
| Earnings | -US$2.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XRTX perform over the long term?
See historical performance and comparison